$0.35
+0.00 (+1.10%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where GCTK is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional
Held by 3 tracked-famous managers (JANE STREET GROUP, LLC, CITADEL ADVISORS LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP) · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Feasibility Study to Evaluate an Intravascular Blood Continuous Glucose SensorNCT06764069Primary outcome: study device safety as evidence by absence of serious procedure or device related adverse event(s).Open-label · Other | Not applicable | Recruiting | Device: Sensor Lead | Diabetes Mellitus | 10 | 2025-02-04 | 2025-01-08 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19